Cambridgeshire, UK, 24 November 2009 - The latest addition to Quotient Bioresearch’s ongoing ‘Evidence’ information series is now available for download. Biomarkers in Respiratory Disease – Part 1: Chronic Obstructive Pulmonary Disease (COPD) is the first white paper in a new series that will explore the value that biomarkers can add to drug discovery and development in important therapeutic areas. The programme includes print and e-newsletters that regularly review the company’s scientific publications, as well as presentations on Quotient Bioresearch expertise and unique integrated clinical service offering – Synthesis-to-Clinic™.
Dr David Griffiths, Business Development Director at Quotient Bioresearch commented: “We are very proud of our information programme. The scientific team at Quotient Bioresearch includes many high calibre individuals, and company experts’ regularly present papers and posters at leading conferences around the world – ICAAC, Biomarker World Congress and AAPS, for example. It was a natural extension to highlight some of our insight and know-how into a range of materials that our clients can access freely.”
COPD is a global health issue that continues to be an important cause of morbidity, mortality, and health-care costs worldwide. In the UK, for example, it affects as many as 3 million people and is soon to be the subject of a new National Clinical Strategy approach from government and healthcare providers. Understanding disease progression – and developing successful therapeutic interventions – requires extensive use of biomarkers. The new Quotient Bioresearch white paper discusses how the combination of biomarkers from three sub-pathologies (oxidative stress, inflammation and tissue remodelling) with physiological assessment of lung function may provide an early indication of disease modification, the long-time goal of many current and prospective COPD treatments.
Please contact us if you would like a copy of the new COPD white paper.